ALK3831 — Competitive Intelligence Brief

ALK3831 (ALK3831) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic (long-acting injectable). Area: Psychiatry/Neurology.

phase 3 Atypical antipsychotic (long-acting injectable) Dopamine D2/D3 receptors Psychiatry/Neurology Small molecule

Target snapshot

ALK3831 (ALK3831) — Alkermes, Inc.. ALK3831 is a long-acting injectable formulation of aripiprazole designed to provide sustained dopamine D2/D3 receptor antagonism for antipsychotic effect.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ALK3831 TARGET	ALK3831	Alkermes, Inc.	phase 3	Atypical antipsychotic (long-acting injectable)	Dopamine D2/D3 receptors
Lansoprazole/Domperidone	Lansoprazole/Domperidone	Neutec Ar-Ge San ve Tic A.Ş	marketed	Proton pump inhibitor + dopamine antagonist combination	H+/K+-ATPase (lansoprazole); dopamine D2/D3 receptors (domperidone)
Aripiprazole or Perphenazine	Aripiprazole or Perphenazine	Johns Hopkins University	marketed	Atypical antipsychotic (aripiprazole); Typical antipsychotic (perphenazine)	Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); Dopamine D2 receptor (perphenazine)
Lamotrigine + Aripiprazole	Lamotrigine + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Anticonvulsant/mood stabilizer + atypical antipsychotic combination	Voltage-gated sodium channels (lamotrigine); dopamine D2/D3 receptors (aripiprazole)
Aripiprazole + desvenlafaxine succinate sustained release	Aripiprazole + desvenlafaxine succinate sustained release	Pfizer	marketed	Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination	Dopamine D2/D3 receptors (aripiprazole); serotonin transporter (SERT) and norepinephrine transporter (NET) (desvenlafaxine)
omeprazole+domperidone SR	omeprazole+domperidone SR	Belarusian Medical Academy of Post-Graduate Education	marketed	Proton pump inhibitor + dopamine antagonist combination	H+/K+-ATPase (omeprazole); dopamine D2/D3 receptors (domperidone)
ropinirole/L-dopa	ropinirole/L-dopa	GlaxoSmithKline	marketed	Dopamine agonist and dopamine precursor combination	Dopamine D2/D3 receptors (ropinirole); dopamine synthesis pathway (L-dopa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic (long-acting injectable) class)

1. Alkermes, Inc. · 1 drug in this class